Safety and adverse effects associated with GLP-1 analogues

Expert Opinion on Drug Safety

Volumn 6, Issue 4, 2007, Pages 417-422

  Stephens, Jeffrey W ^a   Bain, Stephen C ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Diabetes; Exenatide; GLP 1; Hypoglycaemia; Liraglutide

Indexed keywords

EXENDIN 4; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; INSULIN; INSULIN ASPART; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; MEVINOLIN; ORAL ANTIDIABETIC AGENT; PARACETAMOL; PLACEBO; PROTEIN ANTIBODY; SULFONYLUREA; WARFARIN; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; PEPTIDE; VENOM;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE PANCREATITIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; APPETITE; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CHILD HEALTH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG OVERDOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ERUCTATION; FLATULENCE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPERHIDROSIS; HYPOGLYCEMIA; INFERTILITY; INJECTION SITE CONTUSION; INJECTION SITE REACTION; LACTATION; LIPOHYPERTROPHY; LIVER TOXICITY; MONOTHERAPY; MUTAGENESIS; NAUSEA; NEPHROTOXICITY; NERVOUSNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PAPULAR RASH; PREGNANCY OUTCOME; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN IRRITATION; SOMNOLENCE; URTICARIA; VOMITING; WEAKNESS; ANIMAL; METABOLISM;

ANIMALS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; PEPTIDES; VENOMS;

EID: 34548487290     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.6.4.417     Document Type: Review

References (30)

1. DRUCKER DJ: Enhancing incretin action for the treatment of Type 2 diabetes. Diabetes Care (2003) 26(10):2929-2940.
2. JOY SV, RODGERS PT, SCATES AC: Incretin mimetics as emerging treatments for type 2 diabetes. Ann. Pharmacother. (2005) 39(1):110-118.
3. KENDALL DM, KIM D, MAGGS D: Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for Type 2 diabetes. Diabetes Technol. Ther. (2006) 8(3):385-396.
4. KEATING GM: Exenatide. Drugs (2005) 65(12):1681-1692; discussion 1693-1685.
5. NIELSEN LL, YOUNG AA, PARKES DG: Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of Type 2 diabetes. Regul. Pept. (2004) 117(2):77-88.
6. TOURREL C, BAILBE D, MEILE MJ, KERGOAT M, PORTHA B: Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes (2001) 50(7): 1562-1570.
7. XU G, STOFFERS DA, HABENER JF, BONNER-WEIR S: Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes (1999) 48(12):2270-2276.
8. DRUCKER DJ, NAUCK MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes. Lancet (2006) 368(9548):1696-1705.
9. BUSE JB, HENRY RR, HAN J et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with Type 2 diabetes. Diabetes Care (2004) 27(11):2628-2635.
10. DEFRONZO RA, RATNER RE, HAN J et al.: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes. Diabetes Care (2005) 28(5):1092-1100.
11. KENDALL DM, RIDDLE MC, ROSENSTOCK J et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with Type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care (2005) 28(5):1083-1091.
12. BLONDE L, KLEIN EJ, HAN J et al.: Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with Type 2 diabetes. Diabetes Obes. Metab. (2006) 8(4):436-447.
13. BUSE JB, KLONOFF DC, NIELSEN LL et al.: Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with Type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin. Ther. (2007) 29(1):139-153.
14. HEINE RJ, VAN GAAL LF, JOHNS D et al.: Exenatide versus insulin glargine in patients with suboptimally controlled Type 2 diabetes: a randomized trial. Ann, Intern. Med. (2005) 143(8):559-569.
15. NAUCK MA, DURAN S, KIM D et al.: A comparison of twice-daily exenatide and biphasic insulin aspart in patients with Type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia (2007) 50(2):259-267.
16. ZINMAN B, HOOGWERF BJ, DURAN GARCIA S et al.: The effect of adding exenatide to a thiazolidinedione in suboptimally controlled Type 2 diabetes: a randomized trial. Ann. Intern. Med. (2007) 146(7):477-485.
17. EXENATIDE: Injection Package Insert. Amylin Pharmaceuticals, Inc. San Diego, California, USA (2005).
18. MADSBAD S, SCHMITZ O, RANSTAM J, JAKOBSEN G, MATTHEWS DR: Improved glycemic control with no weight increase in patients with Type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care (2004) 27(6): 1335-1342.
19. NAUCKMA, HOMPESCH M, FILIPCZAK R et al.: Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with Type 2 diabetes. Exp. Clin. Endocrinol. Diabetes (2006) 114(8):417-423.
20. DENKER PS, DIMARCO PE: Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care (2006) 29(2):471.
21. FEINGLOS MN, SAAD MF, PI-SUNYER FX, AN B, SANTIAGO O: Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabet. Med. (2005) 22(8):1016-1023.
22. HAUNER H, STOCKAMP B, HAASTERT B: Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp. Clin. Endocrinol. Diabetes (1996) 104(2):106-110.
23. RUVALCABA RH, KLETTER GB: Abdominal lipohypertrophy caused by injections of growth hormone: a case report. Pediatrics (1998) 102(2 Part 1):408-410.
24. CALARA F, TAYLOR K, HAN J et al.: A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin4). Clin. Ther. (2005) 27(2):210-215.
25. KOTHARE PA, SOON DK, LINNEBJERG H et al.: Effect of exenatide on the steady-state pharmacokinetics of digoxin. J. Clin. Pharmacol. (2005) 45(9):1032-1037.
26. YOO BK, TRILLER DM, YOO DJ: Exenatide: a new option for the treatment of Type 2 diabetes. Ann. Pharmacother. (2006) 40(10):1777-1784.
27. BLASE E, TAYLOR K, GAO HY, WINTLE M, FINEMAN M: Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J. Clin. Pharmacol. (2005) 45(5):570-577.
28. KOLTERMAN OG, BUSE JB, FINEMAN MS et al.: Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with Type 2 diabetes. J. Clin. Endocrinol. Metab. (2003) 88(7):3082-3089.
29. SOON D, KOTHARE PA, LINNEBJERG H et al.: Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J. Clin. Pharmacol. (2006) 46(10):1179-1187.
30. RASKIN P, ALLEN E, HOLLANDER P et al.: Initiating insulin therapy in Type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care (2005) 28(2):260-265.